All In Biotech

Drug Trial Radar · NCT07434973

Stratification and Treatment in Early Psychosis Study - PROMOTE

ImPRoving OutcoMes in Individuals at Clinical High Risk fOr Psychosis Using Cannabidiol: a Double-blind, Randomised conTrollEd Trial

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 1, 2029

Study completion Dec 1, 2031

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wellcome Trust; Jazz Pharmaceuticals
First posted
Feb 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is: * To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis. * To confirm the safety of CBD in individuals at clinical high risk for psychosis. The trial is a randomised, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals meeting clinical high risk for psychosis criteria will be recruited for the trial intervention component of the trial. Participants are randomised to treatment with oral CBD 300mg (oral solution 100 mg/mL) twice daily, or a matching placebo, for 104 weeks. By using a battery of clinical outcome assessments, the trial will be able to assess several biomarkers to predict clinical outcomes and response to treatment with CBD. Participants will be invited to provide blood samples, stool samples, cerebrospinal fluid samples (if aged 18 years or over) and complete neuroimaging assessments. Individuals who are not found to have mental illness as defined by DSM-5 criteria will be recruited to a healthy control group, to validate the biomarker component of the trial. Additionally, a control group of healthy volunteers will be recruited who will not take the trial intervention to aid calibration between datasets from sites acquiring MRI data and to inform and validate any possible multivariate signature associated with the CHR-P state, course or outcome by understanding how these measures are different in controls. Healthy controls will also be used for secondary case-control comparisons. Healthy controls will undergo clinical and biomarker assessments only.

Conditions

  • Clinical High Risk for Psychosis (CHR)
  • Clinical High Risk for Psychosis
  • Clinical High Risk for Developing Psychosis

Interventions

  • Cannabidiol (CBD)Drug

    CBD 100 mg/mL Oral Solution

  • PlaceboDrug

    Placebo for Cannabidiol oral solution 100mg/mL oral solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ChaChange from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score)Time frame: Baseline to Week 104

Locations

19 sites in 10 countries. Site status is shown where the registry gives one.

  • MedUni Vienna, Department of Child and Adolescent Psychiatry

    Vienna, Austria

  • Douglas Hospital Research Centre

    Montreal, Canada

  • University Hospital Turku

    Turku, Finland

  • Vivantes Network for Health GmbH

    Berlin, Germany

  • University of Cologne, Faculty of Medicine and University Hospital of Cologne

    Cologne, Germany

  • University Medical Center Schleswig-Holstein

    Lübeck, Germany

  • Ludwig Maximilian University Hospital

    München, Germany

  • National and Kapodistrian University of Athens

    Athens, Greece

  • University of Bari Aldo Moro

    Bari, Italy

  • University of Campania L. Vanvitelli

    Naples, Italy

  • University of Pavia

    Pavia, Italy

  • IRCCS Santa Lucia Foundation

    Roma, Italy

  • Stichting Amsterdam UMC

    Amsterdam, Netherlands

  • Biobizkaia Health Research Institute (Asociación Instituto de Investigación Sanitaria)

    Bilbao, Spain

  • Foundation for Biomedical Research of the Gregorio Marañón Hospital (FIBHGM)

    Madrid, Spain

  • Psychiatric University Hospital (PUK)

    Zurich, Switzerland

  • Cambridgeshire and Peterborough NHS Foundation Trust

    Cambridge, United Kingdom

  • Institute of Psychiatry, Psychology & Neuroscience, King's College London

    London, United Kingdom

  • Oxford Health NHS Foundation Trust (OHFT)

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.